|
| |
Welcome to PharmaShots Weekly
| | | Dec 15 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Retatrutide Rewrites the Playbook: Massive Weight Loss, Game-Changing Joint Benefits
|
|
| | A High-Stakes Pact: Zealand Pharma and OTR Launch $2.5B Push to Transform Metabolic Care
|
|
| | A $2.1B Power Pact: Pfizer and YaoPharma Unite to Accelerate Breakthrough GLP-1 Therapy
|
|
| | Breaking Ground: Relation and Novartis Forge $1.75B Deal to Transform Atopic Disease Research
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Retatrutide Sets a New Standard in Weight Loss and Joint Health
|
| |
|
|
| |
Eli Lilly’s TRIUMPH‑4 Trial Delivers Unprecedented Phase III Results, Rewriting the Future of Obesity Treatment
|
| |
Eli Lilly has shaken the field of metabolic medicine with spectacular Phase III TRIUMPH‑4 data, revealing the kind of results once thought unattainable without surgery. The company’s triple‑agonist therapy, retatrutide (9 mg and 12 mg), combined with lifestyle intervention, delivered significant weight reduction and meaningful pain relief in adults with obesity or overweight and knee osteoarthritis—without including patients with diabetes.
|
| |
Key Outcome
|
| |
TRIUMPH‑4 met its co‑primary endpoints with astonishing clarity:
Average weight loss reached 26.4% (9 mg) and 28.7% (12 mg) compared with just 2.1% in the control group. Patients also reported dramatic improvements in WOMAC pain scores (reductions of 4.5 and 4.4 vs 2.4 points), suggesting not just slimmer bodies—but stronger, pain‑free movement.
|
| |
Equally powerful were the secondary results:
|
| |
| • | ≥25% weight loss: 47.7% (9 mg) and 58.6% (12 mg) vs 1.3%
|
|
| • | ≥30% weight loss: 30.5% and 39.4% vs 0.8%
|
|
| • | ≥35% weight loss: 18.2% and 23.7% vs 0%
|
|
| • | Physical function gain: 4.1 and 4.2 vs 2.1 points
|
|
| • | ≥70% pain reduction: 73% and 67.7% vs 26.2%
|
|
| |
Beyond the scale, retatrutide’s benefits rippled system‑wide—driving a 14 mmHg drop in systolic blood pressure, a three‑fold increase in pain‑free patients (14.1% and 12% vs 4.2%), and consistent metabolic control across all patients. Even under the conservative treatment‑regimen estimand, weight loss remained exceptional—20% and 23.7% (vs 4.6%)—with sustained WOMAC pain improvements of 4 and 3.7 points (vs 2.1).
|
| |
Regulatory Path Ahead
|
| |
In the wake of these transformative findings, Eli Lilly is mobilizing swiftly, advancing its TRIUMPH program toward global regulatory submissions. Additional data expected in 2026, including results for the 4 mg maintenance dose, could position retatrutide as the first therapy to bridge metabolic and musculoskeletal restoration in one treatment.
|
| |
What’s Next
|
| |
The full story of TRIUMPH‑4—to be unveiled at upcoming scientific meetings and through peer‑review publications—marks a defining milestone in the battle against obesity. If confirmed, retatrutide’s dual impact on weight, cardiovascular health, and joint pain could herald a new era where obesity therapy means total body transformation, not compromise.
|
| |
|
| |
| | Deal Watch: High-Impact Pharma Partnerships Driving 2025’s Innovation Cycle
|
|
|
|
|
| |
Zealand Pharma and OTR Forge $2.5B Alliance to Tackle Metabolic Diseases
|
| |
|
|
| |
A New Era for Oral Small-Molecule Innovation
|
| |
Metabolic disease research is gaining fresh momentum as Zealand Pharma and OTR enter a $2.5 billion strategic collaboration—marking one of the most ambitious partnerships in the field to date. The alliance signals both companies’ intent to push the boundaries of oral small-molecule therapy, combining complementary strengths to accelerate discovery and global access.
|
| |
Why This Collaboration Matters
|
| |
The partnership aims to reshape how metabolic disorders are treated, blending OTR’s deep discovery expertise with Zealand’s proven clinical and commercial execution:
|
| |
| • | Multi-program pipeline: The companies will jointly discover and develop a portfolio of novel small-molecule therapies for metabolic diseases.
|
|
| • | Defined roles for maximum synergy: OTR will lead early discovery and preclinical work using its proprietary platform, while Zealand takes charge of global clinical development, regulatory filings, and commercialization.
|
|
| • | Transformative deal value: OTR receives an upfront payment of $20 million, potentially rising to $30 million upon early milestones, with the overall deal worth up to $2.5 billion—mostly tied to commercial success.
|
|
| • | Sustained benefit: OTR is also eligible for tiered single-digit royalties on future global net sales, cementing long-term value in the collaboration.
|
|
| |
A Strategic Step Forward
|
| |
For Zealand, this partnership expands its metabolic disease franchise beyond peptides into new oral modalities. For OTR, it validates its discovery engine on a global stage. Together, the two are setting the stage for a new generation of targeted, accessible metabolic treatments—where innovation meets scalability, and patients stand to benefit most.
|
| |
|
| |
Pfizer and YaoPharma Forge $2.1B Alliance to Advance Novel GLP‑1 Therapy
A Strategic Move to Strengthen Pfizer’s Obesity Pipeline
|
| |
In a bold expansion of its metabolic disease strategy, Pfizer has entered an exclusive global collaboration and license agreement with YaoPharma to advance YP05002, a next-generation GLP‑1 receptor agonist aimed at chronic weight management. The deal underscores Pfizer’s renewed commitment to building a differentiated and durable position in the fast-evolving obesity treatment landscape.
|
| |
Why This Collaboration Matters
|
| |
The partnership brings together Pfizer’s clinical and commercial scale with YaoPharma’s innovation in metabolic therapeutics:
|
| |
| • | Global rights transfer: YaoPharma will complete the ongoing Phase I trial of YP05002 before granting Pfizer exclusive worldwide rights for all further development, manufacturing, and commercialization.
|
|
| • | Significant deal value: Pfizer will pay $150 million upfront, with potential milestones totaling approximately $1.935 billion, plus tiered royalties tied to future product approvals and sales.
|
|
| • | Pipeline synergy: Pfizer plans to test YP05002 in combination with its Phase II GIPR antagonist (PF‑07976016) and other small-molecule candidates, strengthening its integrated approach to obesity management.
|
|
| • | Long-term positioning: The alliance enhances Pfizer’s presence in the GLP‑1 and GIPR therapeutic arena—two of the most promising pathways in metabolic innovation.
|
|
| |
Redefining the Future of Weight Management
|
| |
With obesity emerging as one of the century’s most pressing health challenges, this collaboration signals Pfizer’s intent to move beyond injectables and toward a more comprehensive, accessible portfolio of metabolic treatments. For YaoPharma, it represents a major validation of its science and a global platform for impact—together setting the stage for the next breakthrough in chronic weight management.
|
| |
|
| |
Relation and Novartis Partner in $1.75B Alliance to Uncover New Targets in Atopic Disease
|
| |
A Data-Driven Leap in Immunology Discovery
|
| |
In a significant move toward precision immunology, Relation has entered a multi-program strategic collaboration with Novartis to identify and advance novel therapeutic targets for atopic diseases. The alliance integrates Relation’s cutting-edge Lab-in-the-Loop discovery platform with Novartis’s global development capabilities—promising a new era of biologically informed drug discovery.
|
| |
Why This Collaboration Matters
|
| |
This partnership represents a forward-looking model for how technology-enabled discovery can reshape immune disease research:
|
| |
| • | Platform-powered insight: Relation will lead patient-derived observational studies to build high-resolution functional cell atlases, designed to reveal new biological drivers across atopic conditions.
|
|
| • | Global reach and development: Novartis secures worldwide rights to develop and commercialize any validated targets emerging from the collaboration.
|
|
| • | Robust financial structure: Relation will receive $55 million upfront, including an equity investment and R&D funding, with additional milestone payments totaling up to $1.7 billion across preclinical through commercial stages.
|
|
| • | Shared success model: The agreement also includes tiered royalties on future global net sales, aligning long-term incentives for both partners.
|
|
| |
A New Paradigm for Translational Immunology
|
| |
By bridging data science, experimental biology, and patient-derived insights, the Relation–Novartis alliance aims to unlock mechanisms that have remained hidden in complex immune disorders. Beyond financial scale, this collaboration represents a scientific bet on precision—the belief that understanding disease at a cellular level can pave the way for truly targeted, transformative therapies.
|
| |
|
| |
Viatris to Divest $815M Stake in Biocon Biologics
|
| |
A Strategic Realignment in the Biosimilars Landscape
|
| |
Viatris has announced definitive agreements to divest its stake in Biocon Biologics to Biocon Limited, marking a key step in the company’s evolving focus on strategic portfolio optimization. The transaction, valued at approximately $815 million, underscores Viatris’s commitment to financial and operational flexibility as it repositions for long-term growth.
|
| |
Why This Transaction Matters
|
| |
The divestiture not only reshapes ownership within one of the world’s leading biosimilar platforms but also redefines future competitive boundaries:
|
| |
| • | Balanced transaction structure: Viatris will receive $400 million in cash and $415 million in Biocon shares, expected to be listed on the National Stock Exchange of India with a six-month lock-up period.
|
|
| • | Expanded strategic freedom: The agreement removes biosimilar non-compete restrictions set in 2022—effective immediately for all markets outside the U.S., and from November 2026 within the U.S. market.
|
|
| • | Clear path to close: The transaction is expected to complete in the first quarter of 2026, subject to customary closing conditions.
|
|
| |
A Pivotal Step Toward Independence
|
| |
For Biocon, full ownership of Biocon Biologics strengthens control over its biosimilar portfolio and global commercialization roadmap. For Viatris, the move frees strategic bandwidth to pursue higher-growth opportunities across its branded, complex generic, and novel pipeline. Together, the transaction reshapes the dynamics of the biosimilars ecosystem—signaling a new chapter of agility, focus, and renewed competitive momentum.
|
| |
|
| |
Immutep and Dr. Reddy’s Forge $369M Global Alliance to Advance Eftilagimod Alfa
|
| |
A New Chapter in Immuno-Oncology Collaboration
|
| |
In a landmark deal for immune-oncology innovation, Immutep has entered a strategic collaboration and exclusive licensing agreement with Dr. Reddy’s Laboratories to develop and commercialize Eftilagimod Alfa (efti) across all territories outside North America, Europe, Japan, and Greater China. The partnership bridges Immutep’s immunotherapeutic expertise with Dr. Reddy’s global reach, reinforcing momentum toward next-generation cancer immunotherapies.
|
| |
Why This Collaboration Matters
|
| |
The alliance underscores a shared commitment to advancing accessible, science-driven oncology treatments across emerging markets and beyond:
|
| |
| • | Strategic territorial expansion: The agreement grants Dr. Reddy’s exclusive rights to develop and commercialize efti across high-potential global regions outside the major Western and East Asian markets.
|
|
| • | Strong financial structure: Immutep will receive an upfront payment of $20 million (~AUD 30.2 million), and could earn up to $349.5 million (~AUD 528.4 million) in development, regulatory, and commercial milestones.
|
|
| • | Sustained commercial upside: Immutep will also receive double-digit royalties on future sales within the licensed territories.
|
|
| • | Advancing clinical promise: Efti, a soluble LAG‑3 protein and MHC Class II agonist, is designed to activate antigen-presenting cells and stimulate a targeted anti‑tumor immune response, currently in a Phase III trial for advanced non‑small cell lung cancer and other tumor types.
|
|
| |
A Global Boost for Cancer Immunotherapy
|
| |
For Dr. Reddy’s, the collaboration strengthens its foothold in innovative biologics and oncology, while for Immutep, it opens a powerful commercial pathway across fast‑growing markets. Together, the companies are building a model for how strategic geographic partnerships can accelerate access to transformative therapies—bringing immune-based cancer treatment closer to patients worldwide.
|
| |
|
| |
Lynk Pharmaceuticals and Formation Bio Sign $605M Global Deal for Next-Generation TYK2 Inhibitor
A Strategic Alliance to Elevate Autoimmune Therapeutics
|
| |
Lynk Pharmaceuticals has entered into an exclusive development and licensing agreement with Formation Bio, granting the company worldwide rights (excluding Greater China) to LNK01006, a highly selective TYK2 inhibitor designed to target autoimmune and inflammatory diseases with unprecedented precision. The agreement marks a pivotal step in expanding the reach of Lynk’s innovative kinase portfolio through global partnerships.
|
| |
Why This Collaboration Matters
|
| |
This collaboration underscores the convergence of scientific innovation and strategic commercialization in advancing immunology drug development:
|
| |
| • | Global rights and focus: Formation Bio gains exclusive global rights (outside Greater China) to LNK01006, reinforcing its ambition to build a differentiated autoimmune pipeline.
|
|
| • | Clinical advancement: The program will be led by Formation’s newly established subsidiary, Bleecker Bio, which plans to initiate a Phase I trial in the first half of 2026, following IND clearance by the U.S. FDA.
|
|
| • | Robust financial structure: Lynk Pharmaceuticals will receive an upfront payment, a minority equity stake in Bleecker Bio, and up to approximately $605 million in development, regulatory, and commercial milestones, alongside tiered royalties on future global sales.
|
|
| • | Pipeline innovation: LNK01006’s strong selectivity for TYK2 offers the potential for disease-modifying efficacy across multiple autoimmune conditions with an improved safety profile versus traditional JAK inhibitors.
|
|
| |
A New Frontier in Selective Immunomodulation
|
| |
The Lynk–Formation partnership reinforces a growing trend toward precision-targeted therapy in immune and inflammatory diseases. By uniting Lynk’s kinase expertise with Formation Bio’s development infrastructure, this alliance sets the stage for the next wave of TYK2 innovation—where selectivity meets scalability in pursuit of safer, more effective treatments for patients worldwide.
|
| |
|
| |
Formycon and Zydus Lifesciences Forge Exclusive Partnership to Commercialize FYB206 in North America
A Strategic Move to Expand Access to Immuno-Oncology Biosimilars
|
| |
Formycon has entered an exclusive licensing and supply agreement with Zydus Lifesciences Global FZE—a UAE-based subsidiary of Zydus—to commercialize FYB206, Formycon’s proposed biosimilar to Merck’s Keytruda (pembrolizumab), across the United States and Canada. The collaboration positions both companies to play a central role in broadening patient access to advanced immuno-oncology therapies through high-quality biosimilar alternatives.
|
| |
Why This Collaboration Matters
|
| |
The agreement combines Formycon’s proven development and manufacturing expertise with Zydus’s strong commercial presence across major regulated markets:
|
| |
| • | Defined global roles: Formycon will oversee development, regulatory submissions, manufacturing, and supply of FYB206, while Zydus Lifesciences Global FZE leads commercialization efforts in the licensed markets.
|
|
| • | Regulatory progress: Formycon expects to submit a Biologics License Application (BLA) to the U.S. FDA in the near future, marking a critical milestone toward market entry.
|
|
| • | Therapeutic relevance: FYB206 is a humanized monoclonal antibody targeting the PD‑1 receptor, mirroring the mechanism of the world’s leading checkpoint inhibitor, Keytruda, and aims to deliver comparable efficacy and safety at a lower cost.
|
|
| |
Expanding the Reach of Immunotherapy
|
| |
This partnership signals a strategic step in the maturation of the global oncology biosimilars market. For Formycon, it extends the company’s geographic footprint and reinforces its position as a leader in advanced biosimilar development. For Zydus, it strengthens its presence in high-value biologics across North America—driving a shared vision to make life-extending cancer immunotherapies more accessible to patients worldwide.
|
| |
|
| |
| | Acquisitions That Matter: Redrawing the Future of MRD and Rare Liver Disease
|
|
|
|
|
| |
Natera Acquires Foresight Diagnostics in $450M All-Stock Deal
|
| |
|
|
| |
A Transformative Step Forward in MRD Sensitivity and Solid Tumor Innovation
|
| |
In a major move set to redefine the landscape of molecular residual disease (MRD) testing, Natera has acquired Foresight Diagnostics, integrating its ultra-sensitive PhasED‑Seq phased‑variant technology into Natera’s platform portfolio. The acquisition positions Natera at the forefront of precision oncology, achieving an industry-leading LOD95 of 0.3 ppm with detection capabilities below 0.1 ppm—setting a new benchmark for analytical sensitivity in the field.
|
| |
Why This Acquisition Matters
|
| |
The deal enriches Natera’s MRD leadership and deepens its technological moat across solid tumors and hematologic malignancies:
|
| |
| • | Elevated sensitivity and performance: PhasED‑Seq integration will further enhance Signatera’s performance across solid tumors, improving sensitivity and detection limits for earlier, more confident relapse assessment.
|
|
| • | Comprehensive intellectual property: The acquisition expands Natera’s IP estate to over 500 issued and pending patents, cementing its scientific leadership in MRD and cell‑free DNA analysis.
|
|
| • | Strategic financial structure: The all‑stock transaction includes $275 million upfront and up to $175 million in earnouts linked to revenue and reimbursement milestones.
|
|
| • | Expanded pipeline applications: The integration accelerates Natera’s move into lymphoma, leveraging Foresight’s CLARITY MRD assay and NCCN‑supported clinical data, alongside an enhanced research‑use‑only version available now for biopharma and academic partners.
|
|
| |
A New Era of MRD Precision
|
| |
For Natera, this acquisition represents more than portfolio expansion—it defines the next chapter in MRD innovation, combining unmatched sensitivity, robust clinical validation, and scalable commercialization. With a clinical launch planned for 2026, Natera is poised to deliver the most sensitive and clinically actionable MRD solution to date, reinforcing its role as a leader in transforming cancer detection and monitoring worldwide.
|
| |
|
| |
Mirum Pharmaceuticals to Acquire Bluejay Therapeutics in $820M Deal
A Strategic Expansion in Rare Liver Disease Leadership
|
| |
Mirum Pharmaceuticals has announced an agreement to acquire Bluejay Therapeutics, securing global rights to brelovitug—a promising therapy with both Breakthrough Therapy and PRIME designations. The acquisition enhances Mirum’s strategic position in rare liver diseases, expanding its late-stage pipeline with an asset poised for broad clinical and commercial impact.
|
| |
Why This Acquisition Matters
|
| |
The transaction reflects Mirum’s commitment to deepening its presence in underserved hepatology indications and diversifying its rare disease portfolio:
|
| |
| • | Comprehensive deal structure: Mirum will acquire all outstanding Bluejay shares for $250 million in cash and $370 million in Mirum stock, valuing each Bluejay share at $71.2085.
|
|
| • | Future growth incentives: The agreement includes up to $200 million in sales-based milestones, underscoring Mirum’s confidence in brelovitug’s market potential and clinical differentiation.
|
|
| • | Capital readiness: To fund integration and launch activities, Mirum plans to raise approximately $200 million through a private placement of common stock and pre‑funded warrants, priced at $68.48 per share.
|
|
| • | Path to close: The transaction is expected to complete in Q1 2026, pending customary and regulatory approvals.
|
|
| |
Strengthening a Leadership Position in Hepatology
|
| |
With brelovitug joining its rare liver disease portfolio, Mirum extends its leadership beyond existing bile acid and transport disorder therapies into immune‑mediated and fibrotic liver conditions. The acquisition marks not just a financial milestone but a scientific one—fortifying Mirum’s ambition to bring transformative therapies to patients living with rare, debilitating hepatic diseases worldwide.
|
| |
|
| |
| | Pipeline Momentum: The Clinical Trials Defining the Road Ahead
|
|
|
|
|
| |
Highlights from Early Clinical Data on CT0596 by CARsgen Therapeutics
|
| |
|
|
| |
Multiple Myeloma
|
| |
CARsgen Therapeutics shared encouraging early clinical results for CT0596 in patients with relapsed/refractory multiple myeloma (R/R MM) at ASH 2025. The company plans to advance the program into a Phase Ib registrational study in 2026, following an IND submission expected in the second half of 2025.
|
| |
Key Outcome
In the ongoing Phase I trial, eight heavily pre‑treated patients (median 4.5 prior therapy lines) received CT0596, with enrollment not restricted by NKG2A expression. At a median follow‑up of 4.14 months, six of eight patients achieved a partial response or better, including 3 CR/sCR, 1 VGPR, and 2 PR. Among the six full‑dose patients, five responded, and all six evaluable patients were MRD‑negative by Week 4.
|
| |
| • | Patient 01 maintained sCR and MRD negativity through Month 8.
|
|
| • | Patient 04 improved to PR, showing complete resolution of extramedullary disease after a second infusion.
Overall, CT0596 demonstrated a manageable safety profile, highlighting its promise for patients with advanced myeloma.
|
|
| |
Regulatory Path Ahead
Building on these findings, CARsgen plans to submit an IND application in H2 2025, enabling initiation of the Phase Ib registrational study in 2026 to further evaluate CT0596’s efficacy and safety in a larger patient population.
|
| |
What’s Next
Updated data from the CT0596 program will be presented at future scientific meetings and submitted for peer‑review publication, supporting its development as a potential breakthrough therapy for relapsed/refractory multiple myeloma.
|
| |
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Highlights from the Phase Ia/Ib Study of Bexobrutideg by Nurix Therapeutics
|
| |
Nurix Therapeutics shared updated Phase Ia/Ib results for its BTK degrader bexobrutideg, demonstrating durable efficacy and consistent tolerability in heavily pretreated patients with relapsed/refractory CLL/SLL.
|
| |
Key Outcome
In the Phase Ia study (n=48), bexobrutideg achieved an overall response rate (ORR) of 83%, including two complete responses, with a median progression-free survival (PFS) of 22.1 months across dose levels (50–600 mg once daily). The Phase Ib trial (n=42) reinforced the dose rationale, with an ORR of 83.3% and longer PFS observed at the 600 mg RP2D compared with the 200 mg dose.
Bexobrutideg maintained a favorable and consistent safety profile across all cohorts, including at the RP2D. Notably, robust responses occurred in high-risk subgroups, such as BTKi/BCL‑2 double‑exposed patients and those with BTK, PLCG2, or TP53 mutations.
|
| |
Regulatory Path Ahead
Building on these promising results, Nurix has initiated the global Phase II DAYBreak‑CLL‑201 trial, which is actively enrolling. The company also continues enrollment in the ongoing Phase Ia/Ib NX‑5948‑301 study to further evaluate bexobrutideg’s clinical potential.
|
| |
What’s Next
Comprehensive data from these studies will be presented at upcoming scientific forums and submitted for peer‑review publication, advancing bexobrutideg as a potential next‑generation therapy for patients with relapsed or refractory CLL/SLL.
|
| |
|
| |
Myeloproliferative Neoplasms (ET and MF)
Highlights from Phase I Studies (INCA33989‑101 and INCA33989‑102) by Incyte
|
| |
Incyte presented updated Phase I findings from two studies—INCA33989‑101 and INCA33989‑102—evaluating the safety, tolerability, and activity of INCA033989 in 455 adults (≥18 years) with mutCALR‑positive myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF), at ASH 2025.
|
| |
Key Outcome
In ET patients treated at higher starting doses of INCA033989 (400–2,500 mg; n=30), 90% achieved a hematologic response (HR), including 83.3% complete hematologic response (CHR) and 46.4% maintaining durable CHR ≥12 weeks. At lower doses (24–250 mg; n=25), 88% achieved HR, with 68% CHR and 44% durability of response.
Molecular responses were frequent, rapid, and sustained. Among evaluable ET patients, 96.2% demonstrated a reduction in mutCALR variant allele frequency (VAF), with 52% achieving ≥25% reduction and 31% achieving ≥50% reduction. These reductions typically appeared within 3–6 months and persisted over time, showing deeper, more consistent declines at higher doses.
|
| |
Regulatory Path Ahead
Building on these encouraging results, Incyte is expected to further advance clinical development of INCA033989 in mutCALR‑positive MPNs, optimizing dose selection and exploring its potential across broader patient populations.
|
| |
What’s Next
Full results from both Phase I studies will be presented at future scientific meetings and submitted for peer‑review publication, reinforcing INCA033989’s potential to deliver meaningful, durable molecular and hematologic responses in mutCALR‑positive MPNs.
|
| |
|
| |
Allogeneic Transplant and B‑ALL
|
| |
Highlights from Phase I Studies of Orca‑Q and OrCAR‑T by Orca Bio
|
| |
Orca Bio reported compelling Phase I results for its investigational therapy Orca‑Q, highlighting its potential to transform allogeneic transplant outcomes. The therapy demonstrated rapid neutrophil recovery, low rates of acute and chronic GvHD, reduced infections, and minimal non‑relapse mortality (NRM)—even among patients who did not receive GvHD prophylaxis.
|
| |
Key Outcome
In a comparison of Orca‑Q with tacrolimus (Arm A, n=18) versus without immunosuppression (Arm C, n=26), outcomes were highly consistent across treatment arms. The no‑tac group achieved faster neutrophil engraftment (11 vs. 15 days), comparable 1‑year OS (87% vs. 94%), GRFS (79% vs. 77%), and RFS (87% vs. 88%), while showing lower NRM (0% vs. 6%) and reduced moderate‑to‑severe chronic GvHD at Day 180 (0% vs. 12%).
Patients in the no‑tac cohort also demonstrated stronger immune reconstitution and fewer Grade ≥2 infections (17% vs. 33%), reinforcing Orca‑Q’s favorable immune and safety profile.
|
| |
Across two Phase I studies in high‑risk relapsed/refractory B‑ALL, the OrCAR‑T regimen (Orca‑T + allogeneic CD19/CD22 CAR‑T; n=16) achieved significantly improved survival versus autologous CD19/22 CAR‑T (n=17). At 18 months, PFS was 100% with OrCAR‑T vs. 38.5% with autologous CAR‑T, and OS was 100% vs. 77%, respectively—demonstrating a marked clinical advantage.
|
| |
Regulatory Path Ahead
Building on these encouraging Phase I data, Orca Bio plans to advance Orca‑Q and OrCAR‑T into later‑phase clinical development to confirm their long‑term efficacy and safety in allogeneic transplant and relapsed/refractory B‑ALL populations.
|
| |
What’s Next
Comprehensive results from these Phase I studies will be presented at upcoming scientific meetings and submitted for peer‑review publication, underscoring Orca‑Q’s and OrCAR‑T’s potential to redefine post‑transplant and CAR‑T outcomes in high‑risk hematologic malignancies.
|
| |
|
| |
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
|
| |
Highlights from the Phase III BRUIN CLL‑313 Trial by Eli Lilly
|
| |
Eli Lilly announced positive Phase III results from the BRUIN CLL‑313 trial, evaluating Jaypirca (pirtobrutinib; 200 mg orally once daily) in 282 treatment‑naïve CLL/SLL patients without 17p deletions, compared with bendamustine plus rituximab (n=141 per arm).
|
| |
Key Outcome
As of July 11, 2025, the study met its primary endpoint, demonstrating an 80% improvement in IRC‑assessed progression‑free survival (PFS) versus standard therapy, with consistent benefits observed across all high‑risk subgroups. Investigator‑assessed results, with a median follow‑up of 28.1 months, confirmed these outcomes.
The secondary endpoint, overall survival (OS), showed a favorable trend for Jaypirca, despite 52.9% crossover from the control arm. Further OS analyses are ongoing. The results were presented at ASH 2025 and published in The Journal of Clinical Oncology, reinforcing Jaypirca’s efficacy and durability in the frontline setting.
|
| |
Regulatory Path Ahead
Building on the BRUIN CLL‑313 results, Eli Lilly has initiated regulatory submissions incorporating data from both BRUIN CLL‑313 and BRUIN CLL‑314 to support label expansion of Jaypirca into earlier‑line treatment for CLL/SLL.
|
| |
What’s Next
Full analyses from the BRUIN clinical program will continue to be shared at upcoming scientific meetings and through peer‑review publications, positioning Jaypirca as a potential frontline standard of care for patients with treatment‑naïve CLL/SLL.
|
| |
|
| |
Early‑Stage ER+ Breast Cancer
Highlights from the Phase III lidERA Trial by Roche
|
| |
Roche announced interim Phase III results from the lidERA Breast Cancer trial, evaluating giredestrant (once daily) versus standard‑of‑care endocrine therapy in approximately 4,100 patients with medium‑ or high‑risk stage I–III ER+, HER2‑ breast cancer.
|
| |
Key Outcome
At the interim analysis, the trial met its primary endpoint, showing a 30% improvement in invasive disease‑free survival (iDFS). At 3 years, 92.4% of patients receiving giredestrant were alive and invasive disease‑free, compared with 89.6% in the standard‑of‑care arm. The treatment benefit was consistent across all clinically relevant subgroups.
Giredestrant also achieved a 31% reduction in the risk of distant recurrence and showed a favorable trend in overall survival (OS), with follow‑up analyses ongoing. These data highlight giredestrant’s potential to redefine endocrine therapy in early‑stage ER+ disease.
|
| |
Regulatory Path Ahead
Based on these positive topline results, Roche is expected to advance regulatory discussions supporting potential approval of giredestrant for early‑stage ER+, HER2‑ breast cancer, aiming to expand treatment options for patients at higher risk of recurrence.
|
| |
What’s Next
Comprehensive findings from lidERA were presented at SABCS 2025 and will be submitted for peer‑review publication, further establishing giredestrant’s role as a next‑generation oral SERD for early‑stage ER+ breast cancer.
|
| |
|
| |
| | Regulators Say Yes: The Approvals Shaping What Comes Next
|
|
|
|
|
| |
Approval Alert: This Week’s Game-Changing Regulatory Moves
|
| |
|
|
| |
This week brings a wave of regulatory wins! From groundbreaking oncology and rare disease therapies to new options in immunology and infectious disease, these approvals and designations are set to expand treatment choices and make a real impact for patients worldwide.
|
| |
| • | Junshi Biosciences’ NDA for Roconkibart (IL-17A) was accepted by the NMPA, highlighting a potential new option for patients with moderate to severe plaque psoriasis.
|
|
| • | Boehringer Ingelheim’s Jascayd (Nerandomilast) received NMPA approval, offering a promising therapy for progressive pulmonary fibrosis, a disease with significant unmet need.
|
|
| • | PTC Therapeutics’ Sephience was approved by Health Canada, expanding treatment options for patients with phenylketonuria.
|
|
| • | GSK’s Risvutatug Rezetecan secured FDA Orphan Drug Designation, spotlighting a novel approach in small-cell lung cancer (SCLC).
|
|
| • | BMS’ sBLA for Opdivo in classical Hodgkin lymphoma (cHL) was accepted by the FDA with Priority Review, underscoring its potential to improve outcomes in this challenging hematologic malignancy.
|
|
| • | Amgen’s Uplizna (Inebilizumab-cdon) received FDA approval, marking a new option for patients with generalized myasthenia gravis.
|
|
| • | GSK’s Blujepa was approved by the FDA, introducing a targeted therapy for uncomplicated urogenital gonorrhea (uGC).
|
|
| |
|
| |
| | MedTech on Fast-Forward: Diagnostics, Imaging & Surgery Enter a New Era
|
|
|
|
|
| |
MedTech Surge: Major Advances Reshaping Diagnostics, Imaging & Surgical Care
|
| |
|
|
| |
It’s been a standout week for medtech innovation, with multiple regulatory milestones pushing the boundaries of diagnostics, digital health, and minimally invasive care.
|
| |
| • | EyeYon Medical secured FDA IDE approval to launch a U.S. clinical study of EndoArt, a novel corneal implant designed to address chronic corneal edema and potentially transform management of this vision-limiting condition.
|
|
| • | ResMed received FDA clearance for Smart Comfort, an AI-driven feature that personalizes CPAP therapy settings to enhance patient comfort and improve long-term adherence.
|
|
| • | ProVerum gained FDA approval for the ProVee System, introducing a new minimally invasive option for men with benign prostatic hyperplasia (BPH).
|
|
| • | Lumos Labs announced FDA clearance of LumosityRx, a digital therapeutic built to support cognitive attention and executive function in patients with ADHD.
|
|
| • | Zenflow secured FDA approval for the Zenflow Spring Implant and its delivery system, further expanding the landscape of less invasive solutions for BPH management.
|
|
| |
|
| |
| | Biosimilars Breakthrough: Driving Wider Access in Key Therapeutic Areas
|
|
|
|
|
| |
Biosimilar Breakthrough: This Week’s Key Approval Move
|
| |
|
|
| |
STADA and Bio-Thera have received a CHMP positive opinion for Gotenfia, their biosimilar to Simponi, marking a key step toward expanded access to advanced immunology treatments across Europe.
|
| |
|
| |
| | Purr-fect Progress: A Breakthrough Moment in Feline Health
|
|
|
|
|
| |
Feline Care Focus: A Big Step Forward in Animal Health
|
| |
|
|
0 comments